Back

Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Treatment of acute coronary syndromes in clinical practice Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Samer Al Said

Harvard Medical School, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
Doctor K. Koskinas (Bern, CH)
Abstract Slides Video
Presentation thumbnail
ARCANGELO: an observational, prospective study with acute coronary syndrome patients undergoing percutaneous coronary intervention who receive cangrelor transitioning to oral P2Y12 inhibitors
Doctor L. De Luca (Pavia, IT)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitor for secondary prevention in acute myocardial infarction patients with diabetes mellitus
Professor D. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
The effect of sodium-glucose co-transporter-2 inhibitors following anterior ST-segment elevation myocardial infarction
Doctor G. Incesu (Istanbul, TR)
Abstract Slides
Presentation thumbnail
Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes
Doctor J. Tjerkaski (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of acute coronary syndromes in clinical practice

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Direct Oral Anticoagulants versus Vitamin K Antagonists for the management of left ventricular thrombus after myocardial infarction: A meta-analysis
thumbnail
Congress Presentation
Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates
thumbnail
Congress Presentation
Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources